Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)

[PR Newswire] – THOUSAND OAKS, Calif., May 27, 2015 /PRNewswire/ — Amgen (AMGN) today announced that it will present data from multiple Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab), oprozomib and Nplate® (romiplostim)‎ studies . . . → Read More: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA) Similar Articles: Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Stock Update (NASDAQ:AMGN): Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference Stock Update (NASDAQ:AMGN): Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma